MARKET

HSTO

HSTO

Conatus Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.020
-0.010
-0.97%
Opening 09:32 05/06 EDT
OPEN
1.020
PREV CLOSE
1.030
HIGH
1.030
LOW
1.020
VOLUME
16.74K
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
0.7490
MARKET CAP
36.46M
P/E (TTM)
-0.4339
1D
5D
1M
3M
1Y
5Y
Histogen to Report Second Quarter 2021 Financial Results and Provide Business Update
SAN DIEGO, April 28, Apr 28, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage...
GlobeNewswire · 04/28 20:05
Histogen to Present at the 20th Annual Needham Virtual Healthcare Conference
GlobeNewswire · 03/30 13:00
Histogen Appoints Rochelle Fuhrmann to Board of Directors
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy ...
GlobeNewswire · 03/25 21:05
BRIEF-Histogen Appoints Rochelle Fuhrmann To Board Of Directors
reuters.com · 03/25 20:16
Histogen And Amerimmune Announce First Patient Dosed In Phase 1 Study Of Emricasan In Symptomatic COVID-19 Patients
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19 patients to assess
Benzinga · 03/16 12:02
Canaccord Genuity Thinks Histogen’s Stock is Going to Recover
Canaccord Genuity analyst John Newman maintained a Buy rating on Histogen (HSTO) yesterday and set a price target of $5.00. The company's shares closed
SmarterAnalyst · 03/16 10:06
FDA Clears Histogen's HST-003 Early-Stage Study For Knee Cartilage Regeneration
The FDA has lifted the clinical hold on Histogen Inc's (NASDAQ: 
Benzinga · 03/15 13:04
BRIEF-Histogen Announces Removal Of Clinical Hold By FDA For Hst-003 Ind To Initiate A Phase 1/2 Trial For Knee Cartilage Regeneration
reuters.com · 03/15 12:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSTO. Analyze the recent business situations of Conatus Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSTO stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 1.54M
% Owned: 4.31%
Shares Outstanding: 35.74M
TypeInstitutionsShares
Increased
3
4.21K
New
4
86.96K
Decreased
5
108.20K
Sold Out
3
42.31K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.57%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Chairman/Director
David Crean
President/Chief Executive Officer/Director
Richard Pascoe
Founder/Chief Scientific Officer
Gail Naughton
Chief Financial Officer/Executive Vice President
Susan Knudson
Executive Vice President
Moya Daniels
Senior Vice President
Daniel Ripley
Senior Vice President
Edward Smith
Vice President - Operations
Martin Latterich
Secretary
Thomas Hubka
Director
Rochelle Fuhrmann
Director
Jonathan Jackson
Director
Steven Mento
Director
Brian Satz
Director
Susan Windham-Bannister
Independent Director
Daniel Kisner
No Data
About HSTO
Histogen Inc., formerly Conatus Pharmaceuticals Inc., is a regenerative medicine company. The Company is focused on developing technologies that replace and regenerates tissues in the body. The company’s technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address unmet medical needs. The Company has product candidates in clinical development intended to address and offer treatment for hair loss, dermal filler and treatment for joint cartilage repair. The Company manufactures a soluble multipotent cell conditioned media (CCM), which is the starting material for products for hair growth, skin care and other applications. In addition to this, the Company also manufactures an insoluble extracellular matrix (ECM) for applications such as orthopedics, wound care and soft tissue augmentation.

Webull offers kinds of Histogen Inc stock information, including NASDAQ:HSTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSTO stock methods without spending real money on the virtual paper trading platform.